InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,732.93
(
0.25%
)
US TECH 100
19,427.60
(
0.55%
)
Dow Jones
42,208.22
(
0.20%
)
Brent Oil
74.61
(
0.06%
)
Bitcoin
64,214.31
(
-0.08%
)
Post# of 253211
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 84
Posts 12534
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: None

Monday, 05/22/2017 9:48:07 AM

Monday, May 22, 2017 9:48:07 AM

Post# of 253211
MNTA can't get a break- downgrade

From jbog:

Momenta downgraded to Equal Weight from Overweight at Barclays

Barclays analyst Douglas Tsao downgraded Momenta Pharmaceuticals (MNTA) to Equal Weight citing the likelihood of generic manufacturers, most notably Mylan (MYL), winning approval for generic Copaxone in the coming months. The approvals could come before Momenta and its partner Sandoz win approval themselves for the 40mg dose, Tsao tells investors in a research note.

He lowered his price target for the shares to $17 from $20.

Read more at:
https://thefly.com/landingPageNews.php?id=2555570

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up